---
layout: default
title: Pegfilgrastim
parent: 僅模型預測 (L5)
nav_order: 481
evidence_level: L5
indication_count: 2
---

# Pegfilgrastim
{: .fs-9 }

證據等級: **L5** | 預測適應症: **2** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# PEGFILGRASTIM: From Febrile Neutropenia Prophylaxis to Severe Nonproliferative Diabetic Retinopathy

## One-Sentence Summary

Pegfilgrastim is a pegylated granulocyte colony-stimulating factor (G-CSF) analog, originally used to reduce the incidence of febrile neutropenia in patients receiving myelosuppressive chemotherapy. The TxGNN model predicts it may be effective for **Severe Nonproliferative Diabetic Retinopathy** (and, secondarily, general **Diabetic Retinopathy**), but **no clinical trials or published literature currently support this direction** — the prediction rests on the model score alone.

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Reduction of febrile neutropenia incidence in patients receiving myelosuppressive anticancer chemotherapy |
| Predicted New Indication | Severe Nonproliferative Diabetic Retinopathy |
| TxGNN Prediction Score | 99.89% (rank 2508) |
| Evidence Level | L5 |
| Saudi Arabia Market Status | Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this Evidence Pack. Based on known information, pegfilgrastim is a pegylated G-CSF analog belonging to the hematopoietic growth factor class; its efficacy in reducing chemotherapy-induced neutropenia and febrile neutropenia risk is well established.

The link between a hematopoietic/immune-modulating growth factor and diabetic retinopathy (a microvascular complication involving inflammation, neovascularization, and ischemia) is not pharmacologically obvious from the original indication. G-CSF has been studied in some contexts for angiogenic and neuroprotective effects, which could plausibly underlie a model-detected association, but this remains speculative without supporting mechanistic or clinical data.

A secondary, closely related prediction — general diabetic retinopathy (score 99.73%, rank 4982) — was also flagged by the model, suggesting internal consistency within the TxGNN output rather than independent corroboration.

## Clinical Trial Evidence

Currently no related clinical trials registered

## Literature Evidence

Currently no related literature available

## Safety Considerations

Please refer to the package insert for safety information.

Note: TFDA package insert data (warnings/contraindications) is flagged as a **Blocking** data gap — this drug cannot proceed past initial safety screening (S1) until package insert data is obtained from the TFDA/SFDA source.

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The prediction is supported only by the TxGNN model score (L5) with zero clinical trials, zero literature, and no mechanistic rationale grounded in verified data. The drug is also not marketed in Saudi Arabia, and a **Blocking**-severity safety data gap (TFDA package insert) prevents even a preliminary safety assessment.

**To proceed, the following is needed:**
- TFDA/SFDA package insert (warnings, contraindications) — blocking gap, required before any safety screening
- Verified mechanism of action data from DrugBank or equivalent source
- Targeted literature/preclinical search on G-CSF and diabetic retinopathy to establish or rule out a mechanistic basis
- Monitoring for emerging clinical trials or case reports on this drug-disease pair
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

